Cabozantinib reduced the risk of disease progression or death by 78% with a hazard ratio of 0.22 (96% CI 0.13 - 0.36; p
(C) 2020 Electronic News Publishing, source
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
22.87 USD | +1.55% | +0.75% | -4.67% |
Apr. 12 | North American Morning Briefing : Big Banks Kick -2- | DJ |
Apr. 11 | Barclays Downgrades Exelixis to Equalweight From Overweight, Price Target is $25 | MT |
Cabozantinib reduced the risk of disease progression or death by 78% with a hazard ratio of 0.22 (96% CI 0.13 - 0.36; p
(C) 2020 Electronic News Publishing, source
1st Jan change | Capi. | |
---|---|---|
-4.67% | 6.74B | |
+2.49% | 96.73B | |
-0.15% | 21.31B | |
-16.61% | 21.21B | |
-5.43% | 18.79B | |
-42.14% | 16.37B | |
-27.40% | 13.68B | |
+1.44% | 13.44B | |
+21.29% | 10.98B | |
-21.79% | 8.56B |